Cellectis (NASDAQ:CLLS) Shares Pass Above 50 Day Moving Average – Should You Sell?

Cellectis S.A. (NASDAQ:CLLS)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.93 and traded as high as $3.11. Cellectis shares last traded at $3.04, with a volume of 24,180 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CLLS. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. Barclays started coverage on Cellectis in a research report on Thursday, May 28th. They set an “overweight” rating and a $9.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Cellectis Price Performance

The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $348.18 million, a P/E ratio of -5.34 and a beta of 2.91. The business’s fifty day moving average price is $2.93 and its 200-day moving average price is $3.41.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The company had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC bought a new stake in Cellectis in the 4th quarter worth approximately $34,000. Lido Advisors LLC bought a new position in Cellectis during the first quarter valued at approximately $32,000. Virtu Financial LLC purchased a new position in shares of Cellectis during the third quarter worth approximately $72,000. Acadian Asset Management LLC raised its stake in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 26,461 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.